文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

减低强度预处理联合单次400cGy全身照射及移植后环磷酰胺用于镰状细胞病骨髓移植

Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI.
PubMed 文献 · Blood Adv · 2026-01-01

本研究纳入43例镰状细胞病(SCD)患者(中位年龄23岁),接受含抗胸腺细胞球蛋白、氟达拉滨、环磷酰胺及单次400cGy全身照射(TBI)的减低强度预处理(RIC)方案,联合移植后环磷酰胺(PTCy)预防移植物抗宿主病(GVHD)。中位随访2.43年,5年总生存(OS)概率95.5%,2年无病生存(DFS)概率94.5%,仅2例(5%)移植失败,3/4级急性GVHD累积发生率2.4%,中重度慢性GVHD累积发生率7.3%,部分女性患者卵巢功能恢复。

要点

  • RIC单倍体骨髓移植联合400cGy TBI及PTCy可获得高植入率(移植失败率5%)和低GVHD发生率。
  • 5年OS概率95.5%,2年DFS概率94.5%,中位随访2.43年。
  • 27例女性中12例月经恢复和/或性腺功能正常化,提示可能保留生育力。

核心结论

  • 含400cGy TBI的RIC单倍体骨髓移植联合PTCy毒性低、植入持久且可能保留生育力,可扩大严重SCD的治愈机会。

研究设计与样本

  • 预处理方案包括抗胸腺细胞球蛋白、氟达拉滨、环磷酰胺及单次400cGy TBI;GVHD预防采用PTCy、吗替麦考酚酯和西罗莫司。
  • 主要观察指标为无病生存(DFS)、移植失败、总生存(OS)及GVHD发生率。

主要发现

  • 34例(79%)有≥2项骨髓移植指征,全部患者有≥2种SCD合并症。
  • 中位随访2.43年,5年OS概率95.5%(95%CI 0.87-1.0)。
  • 2年DFS概率94.5%(95%CI 0.87-1.0),仅2例(5%)移植失败。
  • 2例患者在移植后2.5年和6年晚期死亡。
  • 3/4级急性GVHD累积发生率2.4%(95%CI 0-0.07),中重度慢性GVHD累积发生率7.3%(95%CI 0-0.15)。

临床怎么用

  • 对于严重SCD患者,可考虑采用含400cGy TBI的RIC单倍体骨髓移植联合PTCy方案,以获取高植入率和低GVHD风险。
  • 该方案可能保留生育力,适用于有生育需求的患者群体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reduced-intensity conditioning (RIC), haploidentical donors, and posttransplantation cyclophosphamide (PTCy) have overcome many barriers associated with bone marrow transplantation (BMT) for sickle cell disease (SCD). However, initial approaches had high graft failure rates. Our preliminary data suggested increasing the total body irradiation (TBI) dose from 200 to 400 cGy could improve engraftment. This study included patients with SCD aged 2 to 70 years undergoing BMT from November 2014 to January 2025. The regimen included antithymocyte globulin, fludarabine, cyclophosphamide, and single-fraction 400 cGy TBI. Graft-versus-host disease (GVHD) prophylaxis included PTCy, mycophenolate mofetil, and sirolimus. Outcomes measured were disease-free survival (DFS), graft failure, overall survival (OS), and GVHD incidence. A total of 43 patients (median age, 23 years) received a transplant; 34 (79%) had ≥2 indications for BMT, and all had ≥2 SCD comorbidities. Five-year OS probability was 95.5% (95% confidence interval [CI], 0.87-1.0) at a median follow-up of 2.43 years. DFS probability at 2 years was 94.5% (95% CI, 0.87-1.0), with only 2 (5%) graft failures. Two patients died late (2.5 and 6 years) after BMT. The cumulative incidence of grade 3/4 acute GVHD was 2.4% (95% CI, 0-0.07), and that of moderate-severe chronic GVHD was 7.3% (95% CI, 0-0.15). Median time to discontinuation of immunosuppression was 354 days. Of 27 female patients, 12 had return of menses and/or normalized gonadal function. RIC haploidentical BMT with 400 cGy maintained a low-toxicity profile, provides high rates of durable engraftment, and may preserve fertility. This regimen expands the availability of curative therapy for severe SCD. This trial was registered at www.ClinicalTrials.gov as NCT00489281.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Goldenberg M, Varadhan R, Gamper CJ, et al. Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI. Blood Adv. 2026. PMID: 41569644. doi:10.1182/bloodadvances.2025017413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。